manufacturer, packer, or distributor; 502(e)(2)—the labels of a number of the repacked articles of drug failed to bear the common or usual name of each active ingredient contained therein; and 503(b)(4)—a number of the repacked articles of drug were subject to 503(b)(1) and their labels failed to bear the statement "Caution: Federal law prohibits dispensing without prescription."

DISPOSITION: 9–29–61. Default—destruction.

6785. Various prescription drugs. (F.D.C. No. 46086. S. Nos. 50–507/18 R, 50–521/28 R.)

QUANTITY: 5,867 tablets and capsules and 1,475 btls. of liquid at Denver, Colo., in possession of Denver Drug Co.

SHIPPED: On unknown dates, by various drug handlers.

LABEL IN PART: (Some labels) "Physician's Trial Package," "Physician's Sample," "Professional Sample," "Sample – Not To Be Sold," and "Professional Specimen."

RESULTS OF INVESTIGATION: The articles consisted of quantities of prescription drugs repacked from physicians' samples into containers having labels bearing brand names indicative of manufacture outside the State of Colorado, and quantities of prescription drugs which were not yet repacked, originally intended for use as samples, and still in the original sample packages bearing the names and addresses of manufacturers, packers, or distributors outside the State of Colorado.

LIBELED: 7–24–61, Dist. Colo.

CHARGE: 502(a)—while held for sale, the statements "Physician's Trial Package," "Physician's Sample," "Professional Sample," "Sample – Not To Be Sold," "Professional Specimen," and similar wording on the labels of the articles not yet repacked were false and misleading as applied to the articles then in the possession of a repacker and intended for sale and not then intended for use as "complimentary – not for sale" samples for physicians and others lawfully engaged in dispensing prescription drugs; 502(f)(1)—the labeling of a number of the repacked articles failed to bear adequate directions for use and they were not exempt from that requirement since they were subject to the provisions of 503(b)(1) and their labels failed to bear an identifying lot number from which it was possible to determine the complete manufacturing history as is required by regulations; and 503(b)(4)—the repacked articles of drug were subject to 503(b)(1) and their labels failed to bear the statement "Caution: Federal law prohibits dispensing without prescription."

DISPOSITION: 10–6–61. Default—destruction.

6786. Various prescription drugs. (F.D.C. No. 46206. S. No. 59–038 R.)

QUANTITY: Approximately 3,000 pkgs. at Atlanta, Ga., in possession of Crews Drug Co., Inc.

SHIPPED: On unknown dates, by various drug handlers.

LABEL IN PART: (Some labels) "Professional Sample," "Physician's Sample," "Complimentary," "Professional Trial Package," "Professional Sample Not to Be Sold," "Clinical Trial Supply," and "Physician's sample not to be sold."

RESULTS OF INVESTIGATION: The articles consisted of quantities of prescription drugs repacked by Crews Drug Co., Inc., from physicians' samples into containers having labels bearing brand names indicative of manufacture